Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

IMMUNOTHERAPY OF RHEUMATIC DISEASES BASED ON UNDERSTANDING GENETIC PREDISPOSITION TO THE DEVELOPMENT OF THESE DISEASES RHEUMATIC DISEASE CLINICS OF NORTH AMERICA Fathman, C. G. 1992; 18 (4): 915-926

Abstract

During the past two decades, investigators have made great inroads in understanding markers of genetic predisposition to the development of rheumatic diseases. An important question that must be addressed by investigators and clinicians is whether this knowledge will ultimately benefit patients, either through genetic counseling or predictions for beneficial therapeutic intervention. This article discusses various disease mechanisms and modes of immunotherapy such as anti-CD4, major histocompatibility complex blockade, and T-cell receptor-based and determinant-induced responsiveness.

View details for Web of Science ID A1992LA28000012

View details for PubMedID 1280848